AN2 Therapeutics Inc’s recent filing unveils that its Director Zakrzewski Joseph S unloaded Company’s shares for reported $1.91 million on Jan 18 ’24. In the deal valued at $19.11 per share,100,000 shares were sold. As a result of this transaction, Zakrzewski Joseph S now holds 405,880 shares worth roughly $1.22 million.
Then, Aziz Kabeer sold 100,000 shares, generating $1,965,000 in total proceeds. Upon selling the shares at $19.65, the Director now owns 377,542 shares.
Before that, Adjuvant Global Health Technol sold 84,093 shares. AN2 Therapeutics Inc shares valued at $1,652,427 were divested by the 10% Owner at a price of $19.65 per share. As a result of the transaction, Adjuvant Global Health Technol now holds 1,995,958 shares, worth roughly $6.01 million.
JMP Securities upgraded its AN2 Therapeutics Inc [ANTX] rating to a Mkt outperform from a a Mkt perform in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who decreased its forecast for the stock in mid February from “an Outperform” to “a Market perform”. Oppenheimer also remained covering ANTX and has decreased its forecast on February 12, 2024 with a “Perform” recommendation from previously “an Outperform” rating. JMP Securities revised its rating on February 12, 2024. It rated ANTX as “a Mkt perform” which previously was an “a Mkt outperform”.
Price Performance Review of ANTX
On Friday, AN2 Therapeutics Inc [NASDAQ:ANTX] saw its stock fall -7.38% to $3.01. Over the last five days, the stock has lost -7.38%. AN2 Therapeutics Inc shares have fallen nearly -85.31% since the year began. Nevertheless, the stocks have fallen -66.29% over the past one year. While a 52-week high of $22.22 was reached on 01/10/24, a 52-week low of $2.72 was recorded on 03/06/24. SMA at 50 days reached $7.26, while 200 days put it at $12.55. A total of 0.53 million shares were traded, compared to the trading of 0.25 million shares in the previous session.
Levels Of Support And Resistance For ANTX Stock
The 24-hour chart illustrates a support level at 2.90, which if violated will result in even more drops to 2.79. On the upside, there is a resistance level at 3.20. A further resistance level may holdings at 3.40. The Relative Strength Index (RSI) on the 14-day chart is 29.59, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.04, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.78%. Stochastics %K at 32.20% indicates the stock is a holding.
How much short interest is there in AN2 Therapeutics Inc?
A steep rise in short interest was recorded in AN2 Therapeutics Inc stocks on Mar 15, 2024, dropping by 16830.0 shares to a total of 0.32 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 0.34 million shares. There was a decline of -5.27%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 1.55% of the overall stock float, the days-to-cover ratio (short ratio) fell to 0.63.
